Current treatment options for systemic fungal infections remain limited. The development of new antifungals is complicated by the structural and metabolic similarities among fungal and host cells, and the consequent potential for host toxicity. The commonly used polyene and triazole antifungals, which target fungal cell membrane sterols, also affect the stability and production of mammalian cell membrane cholesterol. The recently developed echinocandins are more specific for fungal targets, however they are ineffective in the treatment of Histoplasma capsulatum and Cryptococcus neoformans, leaving the host-toxic polyenes and triazoles as the only methods for treatment of infections caused by these pathogens. From a library of small molecules with structural similarities to purines (e.g., ATP/GTP, NADP, etc.), we identified a series of thiazole-based compounds that have potent antifungal activity against Histoplasma capsulatum and Cryptococcus neoformans. Importantly, these compounds inhibit not only fungal cells in culture but also fungal cells that reside within mammalian host cells following infection. Treatment of Histoplasma-infected macrophages with the thiazole-based antifungals protects host cells from Histoplasma- induced cell death. To mature the top hit antifungal thiazole into a lead candidate for drug development and to better understand its mode of action, this research proposal seeks to identify the cellular target(s) of the antifungal thiazole using affinity and chemical proteomics and to provide initial n vivo efficacy and toxicity studies using an animal model. In addition, derivatives of the thiazole will be prepared and tested to define the structural features necessary for antifungal activity and to improve its chemical properties and maximize antifungal potency.
Treatment of infectious disease caused by fungal pathogens is limited by the lack of therapeutics that are both effective against the fungus and non-toxic to the human host. Recently developed antifungals have proven ineffective against the more virulent fungal pathogens including Histoplasma capsulatum, which, unlike opportunistic fungal pathogens, can cause disease regardless of the immune status of the host. This proposal will further develop a recently identified antifungal compound that shows promise for selective inhibition of the primary human fungal pathogen Histoplasma capsulatum as well as the opportunistic fungal pathogen Cryptococcus neoformans.
|Ishita, Keisuke; Stefanopoulos, Stavros; Khalil, Ahmed et al. (2018) Synthesis and biological evaluation of aminothiazoles against Histoplasma capsulatum and Cryptococcus neoformans. Bioorg Med Chem 26:2251-2261|
|Goughenour, Kristie D; Rappleye, Chad A (2017) Antifungal therapeutics for dimorphic fungal pathogens. Virulence 8:211-221|
|Goughenour, Kristie D; Balada-Llasat, Joan-Miquel; Rappleye, Chad A (2015) Quantitative Microplate-Based Growth Assay for Determination of Antifungal Susceptibility of Histoplasma capsulatum Yeasts. J Clin Microbiol 53:3286-95|
|Khalil, Ahmed; Edwards, Jessica A; Rappleye, Chad A et al. (2015) Design, synthesis, and biological evaluation of aminothiazole derivatives against the fungal pathogens Histoplasma capsulatum and Cryptococcus neoformans. Bioorg Med Chem 23:532-47|